Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novo Nordisk in Danish police probe for Tresiba disclosure delay

This article was originally published in Scrip

Executive Summary

Novo Nordisk has been reported to the police by the Danish Financial Supervisory Authority for failing to disclose inside information as soon as possible. The reporting relates to the company's receipt of the complete response letter (CRL) from the US FDA for Tresiba (insulin degludec) and Ryzodeg (insulin degludec/insulin aspart) on the evening of Friday 8 February 2013. Novo published the FDA's decision in a company announcement on Sunday 10 February (, 11 February 2013). However, the Danish Financial Supervisory Authority is of the opinion that Novo should have issued an announcement on the Friday evening.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts